Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
https://ascopubs.org/doi/10.1200/JCO-25-02083. Accessed April 15, 2026.Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN. Available at
More news about: AbbVie
Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results
of Gynecologic Oncology (SGO) Annual Meeting, AbbVie presented Phase 2 data for Elahere in platinum-sensitive ovarian cancer (PSOC). Results from the IMGN853-0420 trial showed a more than 60 percent objective response rate (ORR) and consistent safety findings with Elahere plus carboplatin followed by a
More news about: AbbVie
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
and efficacy of mirvetuximab soravtansine-gynx for use as a combination therapy in PSOC have not been established.About the IMGN853-0420 TrialIMGN853‑0420 (
More news about: AbbVie